Cytogen, Inc. (KOSDAQ:217330)

Market Cap	93.09B +0.6%
Revenue (ttm)	26.05B +138.8%
Net Income	-12.34B
EPS	-535.00
Shares Out	23.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,806
Average Volume	254,533
Open	4,040.00
Previous Close	4,040.00
Day's Range	3,865.00 - 4,190.00
52-Week Range	2,260.00 - 11,200.00
Beta	-0.03
RSI	39.29
Earnings Date	May 15, 2026

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217330

Financial Performance

In 2025, Cytogen's revenue was 26.05 billion, an increase of 138.80% compared to the previous year's 10.91 billion. Losses were -12.34 billion, -27.89% less than in 2024.